Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) passed a US Food and Drug Administration's current good manufacturing practice inspection conducted in September 2024.
The inspection focused on the company's Lianyungang production facility in China's Jiangsu province, which evaluated its production quality management systems, according to a Thursday filing with the Shanghai bourse.